Hologic’s RSNA 2023 unveiling presented Genius AI Detection 2.0, a groundbreaking technology slashing false-positive markings by 70%. Alongside SecurView 12.0, it streamlines lesion correlation for expedited reviews. Erik Anderson emphasized their commitment to enhancing cancer detection and workflow. This reaffirms Hologic’s dedication to refining AI solutions based on customer feedback, fostering continuous innovation in breast health.
The 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA 2023) in Chicago, IL witnessed Hologic, Inc. taking strides in unveiling groundbreaking advancements in AI solutions, particularly focused on women’s health imaging. This pioneering global leader in breast imaging showcased an array of innovations designed to harness AI technology for significantly enhancing cancer detection, optimizing radiologist workflow, and elevating overall patient satisfaction.
One of the standout highlights presented was the introduction of Genius AI Detection 2.0, marking a significant leap in Hologic’s suite of Breast and Skeletal Health Solutions. This next-generation deep-learning technology aims to bolster the detection capabilities of breast cancer while markedly reducing the occurrence of false-positive markings per case. Comparative analyses against Hologic’s existing ImageChecker CAD solution showcased an impressive milestone: a remarkable 70% reduction in false-positive markings per case. This pivotal advancement is poised to instill greater confidence in radiologists, enabling them to identify suspicious lesions more accurately, consequently minimizing the need for unnecessary reviews. Accompanying this breakthrough, the unveiling of the SecurView 12.0 further complements the innovation. It extends the platform’s capabilities by enabling direct reading of breast ultrasound cases within the SecurView viewer. The integration of Genius AI Detection 2.0 with the new automated lesion correlation feature significantly expedites the review process for specific lesions, as outlined in the company’s overview.
Erik Anderson, Division President of Breast and Skeletal Health Solutions at Hologic, expressed profound enthusiasm for these groundbreaking solutions. He underscored their pivotal role in supporting radiologists with enhanced cancer detection and streamlining workflows, aspects critically vital for their clientele. Anderson also emphasized the company’s unwavering commitment to advancing breast health through cutting-edge technology, aiming to engage with industry leaders and reaffirm Hologic’s dedication at the RSNA meeting.
The debut of Genius AI Detection 2.0 underscores Hologic’s commitment to constant evolution and refinement in its AI roadmap. The company’s ongoing dedication to incorporating customer feedback, leveraging research insights, and continually enhancing its offerings serves as a foundation for future iterations of Genius AI Detection technology and the development of new AI products. Hologic’s ongoing exploration and research efforts are geared towards potential product features that aim to further elevate accuracy and efficiency in breast care. These include real-time image quality feedback, short-term risk assessments, automated reporting tools, and intelligent triage functionalities.
Attendees at the RSNA 2023 experienced an immersive demonstration of Hologic’s comprehensive portfolio, featuring the Dimensions mammography portfolio, Affirm Contrast Biopsy software, I-View Contrast Enhanced Mammography software, and a suite of cutting-edge breast biopsy and surgery solutions. Additionally, Hologic conducted an array of highly informative sessions, including a CME-accredited symposium and insightful lunch-and-learn sessions. Topics covered during these sessions encompassed diverse areas such as advancements in Breast Imaging with Contrast-Enhanced Mammography, the current landscape of AI Applications in Mammography, and a Comprehensive Approach to Localization, providing invaluable insights into the benefits of wire versus wire-free breast localization techniques.
The exhibition at RSNA 2023 showcased Hologic’s steadfast commitment to pioneering advancements in women’s health through state-of-the-art technology. For those seeking more information, a visit to www.hologic.com will offer deeper insights into these cutting-edge developments.
Hologic’s RSNA 2023 exhibit unveiled innovative AI solutions like Genius AI Detection 2.0, significantly reducing false positives. This, combined with SecurView 12.0, exemplifies their commitment to streamlining lesion correlation for faster reviews. Erik Anderson’s emphasis on improved cancer detection and workflow signifies Hologic’s ongoing dedication to advancing breast health. Through continuous innovation and customer-centric approaches, Hologic reaffirms its position at the forefront of women’s health imaging technology.
